NeoGenomics (NASDAQ:NEO) Director Lynn Tetrault Sells 5,307 Shares

NeoGenomics, Inc. (NASDAQ:NEO) Director Lynn Tetrault sold 5,307 shares of the business’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $11.29, for a total transaction of $59,916.03. Following the completion of the transaction, the director owned 91,422 shares of the company’s stock, valued at approximately $1,032,154.38. The trade was a 5.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

NeoGenomics Price Performance

Shares of NASDAQ NEO opened at $11.47 on Friday. NeoGenomics, Inc. has a twelve month low of $4.72 and a twelve month high of $13.74. The firm has a market cap of $1.49 billion, a P/E ratio of -14.90 and a beta of 1.82. The company has a 50 day moving average of $9.01 and a 200 day moving average of $10.31. The company has a quick ratio of 4.06, a current ratio of 4.42 and a debt-to-equity ratio of 0.41.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, April 28th. The medical research company reported $0.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.01. NeoGenomics had a negative net margin of 13.30% and a negative return on equity of 2.80%. The company had revenue of $186.67 million during the quarter, compared to analyst estimates of $184.54 million. NeoGenomics’s revenue was up 11.3% on a year-over-year basis. As a group, research analysts expect that NeoGenomics, Inc. will post -0.15 EPS for the current fiscal year.

Analysts Set New Price Targets

NEO has been the subject of a number of recent analyst reports. Weiss Ratings upgraded shares of NeoGenomics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. William Blair restated a “market perform” rating on shares of NeoGenomics in a report on Monday, March 16th. Benchmark upgraded shares of NeoGenomics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Wednesday, April 29th. Leerink Partners upgraded shares of NeoGenomics from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $12.00 to $25.00 in a research note on Wednesday, April 29th. Finally, TD Cowen boosted their target price on shares of NeoGenomics from $13.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Six equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $13.86.

Institutional Investors Weigh In On NeoGenomics

A number of hedge funds have recently added to or reduced their stakes in NEO. Aster Capital Management DIFC Ltd raised its stake in NeoGenomics by 42.5% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 3,341 shares of the medical research company’s stock valued at $26,000 after buying an additional 997 shares during the last quarter. First Horizon Corp increased its stake in shares of NeoGenomics by 52.6% in the 4th quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock worth $30,000 after purchasing an additional 865 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of NeoGenomics in the 2nd quarter worth $32,000. Caitong International Asset Management Co. Ltd increased its stake in shares of NeoGenomics by 110.2% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock worth $35,000 after purchasing an additional 1,556 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new stake in shares of NeoGenomics in the 4th quarter worth $39,000. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.